Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2020

11.10.2019 | Original Article

Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model

verfasst von: Kazuhiro Tada, Yukio Iwashita, Ken Shiraiwa, Hiroki Uchida, Yusuke Oshima, Yuhki Sato, Hiroaki Nakanuma, Teijiro Hirashita, Takashi Masuda, Yuichi Endo, Yu Takeuchi, Masayuki Ohta, Hiroki Itoh, Masafumi Inomata

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemotherapy after hepatectomy for colorectal liver metastasis has not been established, due to the toxic side effects, which are likely related to impaired drug clearance during liver regeneration. We investigated the pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil (5-FU) during liver regeneration after major hepatectomy in a rat model.

Methods

Thirty-six male Wistar rats were divided into control (C), control with chemotherapy (CC), hepatectomy (H), and hepatectomy with chemotherapy (HC) groups. The CC and HC groups were administered 5-FU for 4 days. Plasma 5-FU, liver weight, and liver dihydropyrimidine dehydrogenase (DPD) were measured. The ileal villous height was measured to determine adverse effects.

Results

The area under the curve and maximum plasma concentration of 5-FU increased by up to 51% and 32%, respectively, in the HC group compared to the CC group. The liver regeneration rate was significantly lower in the HC group than in the H group (67.3 ± 7.4 vs 33.0 ± 5.7%, p < 0.001). The HC group had a significantly lower liver DPD than the CC group (4.4 ± 1.1 mg vs 6.9 ± 1.1 mg, p < 0.01). The HC group had a significantly lower ileal villous height than the CC group (253 ± 40 μm vs. 318 ± 36 μm, p < 0.05).

Conclusions

Reduction of the total liver DPD following major hepatectomy caused increased plasma 5-FU levels and 5-FU-associated toxicity.
Literatur
1.
Zurück zum Zitat Martin LW, Warren RS (2000) Current management of colorectal liver metastases. Surg Oncol Clin N Am 9:853–876 (discussion 77–8) CrossRef Martin LW, Warren RS (2000) Current management of colorectal liver metastases. Surg Oncol Clin N Am 9:853–876 (discussion 77–8) CrossRef
2.
Zurück zum Zitat Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825 (discussion 25–7) CrossRef Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825 (discussion 25–7) CrossRef
3.
Zurück zum Zitat Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999CrossRef Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999CrossRef
4.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRef Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRef
5.
Zurück zum Zitat Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:4287–4299CrossRef Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:4287–4299CrossRef
6.
Zurück zum Zitat Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M et al (2016) Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: a Randomized Controlled Trial. PLoS One 11:e0162400CrossRef Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M et al (2016) Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: a Randomized Controlled Trial. PLoS One 11:e0162400CrossRef
7.
Zurück zum Zitat Carlsson G, Graf W, Gustavsson BG, Glimelius B, Pahlman L, Spears PC (1990) Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer 26:874–876CrossRef Carlsson G, Graf W, Gustavsson BG, Glimelius B, Pahlman L, Spears PC (1990) Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur J Cancer 26:874–876CrossRef
8.
Zurück zum Zitat Sorbye H, Dahl O (2003) Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 42:827–831CrossRef Sorbye H, Dahl O (2003) Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 42:827–831CrossRef
9.
Zurück zum Zitat Van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, Van Gennip AH (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79:620–626CrossRef Van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, Van Gennip AH (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79:620–626CrossRef
10.
Zurück zum Zitat van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950CrossRef van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950CrossRef
11.
Zurück zum Zitat Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, Van Gennip AH, De Vries EG (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028–1033CrossRef Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, Van Gennip AH, De Vries EG (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028–1033CrossRef
12.
Zurück zum Zitat Zhang S, Liu Y, Xiang D, Yang J, Liu D, Ren X, Zhang C (2018) Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. Biomed Pharmacother 106:910–916CrossRef Zhang S, Liu Y, Xiang D, Yang J, Liu D, Ren X, Zhang C (2018) Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. Biomed Pharmacother 106:910–916CrossRef
13.
Zurück zum Zitat Komori Y, Iwashita Y, Ohta M, Kawano Y, Inomata M, Kitano S (2014) Effects of different pressure levels of CO2 pneumoperitoneum on liver regeneration after liver resection in a rat model. Surg Endosc 28:2466–2473CrossRef Komori Y, Iwashita Y, Ohta M, Kawano Y, Inomata M, Kitano S (2014) Effects of different pressure levels of CO2 pneumoperitoneum on liver regeneration after liver resection in a rat model. Surg Endosc 28:2466–2473CrossRef
14.
Zurück zum Zitat Martins PN, Theruvath TP, Neuhaus P (2008) Rodent models of partial hepatectomies. Liver Int 28:3–11CrossRef Martins PN, Theruvath TP, Neuhaus P (2008) Rodent models of partial hepatectomies. Liver Int 28:3–11CrossRef
15.
Zurück zum Zitat Rupp ME, Ulphani JS, Fey PD, Mack D (1999) Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Infect Immun 67:2656–2659CrossRef Rupp ME, Ulphani JS, Fey PD, Mack D (1999) Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Infect Immun 67:2656–2659CrossRef
16.
Zurück zum Zitat Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T (1990) Moment analysis program available on Microsoft Excel®. Drug Metab Pharmacokinet 14:286–293CrossRef Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T (1990) Moment analysis program available on Microsoft Excel®. Drug Metab Pharmacokinet 14:286–293CrossRef
17.
Zurück zum Zitat Tabata K, Yamaoka K, Yasui H, Fukuyama T, Nakagawa T (1996) Influence of pentobarbitone on in vivo local disposition of diclofenac in rat liver. J Pharm Pharmacol 48:866–869CrossRef Tabata K, Yamaoka K, Yasui H, Fukuyama T, Nakagawa T (1996) Influence of pentobarbitone on in vivo local disposition of diclofenac in rat liver. J Pharm Pharmacol 48:866–869CrossRef
18.
Zurück zum Zitat Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305:2335–2342CrossRef Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305:2335–2342CrossRef
19.
Zurück zum Zitat Haga J, Shimazu M, Wakabayashi G, Tanabe M, Kawachi S, Fuchimoto Y, Hoshino K, Morikawa Y, Kitajima M, Kitagawa Y (2008) Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl 14:1718–1724CrossRef Haga J, Shimazu M, Wakabayashi G, Tanabe M, Kawachi S, Fuchimoto Y, Hoshino K, Morikawa Y, Kitajima M, Kitagawa Y (2008) Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver Transpl 14:1718–1724CrossRef
20.
Zurück zum Zitat Nagasue N, Kobayashi M, Iwaki A, Yukaya H, Kanashima R, Inokuchi K (1978) Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat. Cancer 41:435–443CrossRef Nagasue N, Kobayashi M, Iwaki A, Yukaya H, Kanashima R, Inokuchi K (1978) Effect of 5-fluorouracil on liver regeneration and metabolism after partial hepatectomy in the rat. Cancer 41:435–443CrossRef
21.
Zurück zum Zitat Hubert C, Dahrenmoller C, Marique L, Jabbour N, Gianello P, Leclercq I (2015) Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. Eur J Surg Oncol 41:1471–1478CrossRef Hubert C, Dahrenmoller C, Marique L, Jabbour N, Gianello P, Leclercq I (2015) Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. Eur J Surg Oncol 41:1471–1478CrossRef
22.
Zurück zum Zitat Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77:441–451CrossRef Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH, Larra FG (1996) Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77:441–451CrossRef
23.
Zurück zum Zitat Gamelin E, Boisdron-Celle M (1999) Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer–status of the art. Crit Rev Oncol Hematol 30:71–79CrossRef Gamelin E, Boisdron-Celle M (1999) Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer–status of the art. Crit Rev Oncol Hematol 30:71–79CrossRef
24.
Zurück zum Zitat Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G et al (2018) Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105:397–407CrossRef Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G et al (2018) Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105:397–407CrossRef
Metadaten
Titel
Pharmacokinetic and toxicodynamic evaluation of 5-fluorouracil administration after major hepatectomy in a rat model
verfasst von
Kazuhiro Tada
Yukio Iwashita
Ken Shiraiwa
Hiroki Uchida
Yusuke Oshima
Yuhki Sato
Hiroaki Nakanuma
Teijiro Hirashita
Takashi Masuda
Yuichi Endo
Yu Takeuchi
Masayuki Ohta
Hiroki Itoh
Masafumi Inomata
Publikationsdatum
11.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2020
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03969-1

Weitere Artikel der Ausgabe 2/2020

Cancer Chemotherapy and Pharmacology 2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.